Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

Author： Parkes David G   Mace Kenneth F   Trautmann Michael E  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.8, Iss.2, 2013-02, pp. : 219-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy

By  

Current Clinical Pharmacology, Vol. 7, Iss. 3, 2012-08 ,pp. : 214-228

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Thiadiazole as an Antidiabetic Agent- A Review

By  

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 2, 2014-02 ,pp. : 136-153

Bentham Science Publishers

Access to resources Recommend Favorite

GLP-1 (7-36) amide confers cardiovascular benefits

By  

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Development of Pyrazole Compounds as Antidiabetic Agent: A Review

By  

Letters in Drug Design & Discovery, Vol. 11, Iss. 5, 2014-06 ,pp. : 686-703

Bentham Science Publishers

Access to resources Recommend Favorite

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

By Briones Mariele   Bajaj Mandeep  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite